2020年肾衰竭临床试验结局的国际共识定义
国际肾脏病学会召开多利益相关方会议,基于64项随机试验的163个肾衰竭相关定义,经83名来自18个国家的参与者迭代制定共识。共识推荐临床试验肾衰竭结局采用复合终点,包括接受肾移植、启动维持性透析和肾衰竭死亡,也可包括基于肾小球滤过率实验室测量的结局。
要点
- 临床试验肾衰竭复合终点包括肾移植、维持性透析和肾衰竭死亡。
- 复合终点可纳入持续低肾小球滤过率或持续百分比下降。
- 定义需适用于不同资源环境并避免不适当复杂性。
核心结论
- 临床试验肾衰竭结局应采用包含肾移植、维持性透析和肾衰竭死亡的复合终点,并可纳入基于肾小球滤过率实验室测量的结局。
研究设计与样本
- 国际肾脏病学会召开国际多利益相关方会议,核心组基于64项随机试验的163个相关定义,经迭代流程制定共识定义,并由83名来自18个国家的参与者审核。
主要发现
- 会议参与者共识认为临床试验肾衰竭结局应包含肾移植、启动维持性透析和肾衰竭死亡,也可包括持续低肾小球滤过率和持续肾小球滤过率百分比下降。
关键数值与推荐
- 临床试验肾衰竭复合终点包括接受肾移植、启动维持性透析和肾衰竭死亡。
- 复合终点可包括仅基于实验室测量的肾小球滤过率结局:持续低肾小球滤过率和持续肾小球滤过率百分比下降。
临床怎么用
- 在临床试验中采用该共识复合终点定义肾衰竭,以统一不同试验间的结局报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney failure is an important outcome for patients, clinicians, researchers, healthcare systems, payers, and regulators. However, no harmonized international consensus definitions of kidney failure and key surrogates of progression to kidney failure exist specifically for clinical trials. The International Society of Nephrology convened an international multi-stakeholder meeting to develop consensus on this topic. A core group, experienced in design, conduct, and outcome adjudication of clinical trials, developed a database of 64 randomized trials and the 163 included definitions relevant to kidney failure. Using an iterative process, a set of proposed consensus definitions were developed and subsequently vetted by the larger multi-stakeholder group of 83 participants representing 18 different countries. The consensus of the meeting participants was that clinical trial kidney failure outcomes should be comprised of a composite that includes receipt of a kidney transplant, initiation of maintenance dialysis, and death from kidney failure; it may also include outcomes based solely on laboratory measurements of glomerular filtration rate: a sustained low glomerular filtration rate and a sustained percent decline in glomerular filtration rate. Discussion included important considerations, such as (i) recognition of existing nomenclature for kidney failure; (ii) applicability across resource settings; (iii) ease of understanding for all stakeholders; and (iv) avoidance of inappropriate complexity so that the definitions can be used across ranges of populations and trial methodologies. The final definitions reflect the consensus for use in clinical trials.
引用
- Levin A, Agarwal R, Herrington WG, et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int. 2020. PMID: 32998816. doi:10.1016/j.kint.2020.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。